SPARC gains over 5% on complaint withdrawal

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sun Pharma Advanced Research Company (SPARC) share price added 5.6 percent intraday on December 9 on the withdrawal of complaint filed against the company.

Abraxis Bioscience LLC has dismissed the patent infringement complaint filed against SPARC regarding SPARC’s New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension), as per the company release.

“We are very pleased that Abraxis Bioscience LLC has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals,” said Anil Raghavan, CEO of SPARC.

The company will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

At 11:25 hrs, Sun Pharma Advanced Research Company was quoting at Rs 160, up Rs 6.30, or 4.10 percent, on the BSE.